Company Name, Ticker, Customers, else..

Aceragen Inc (NASDAQ: ACGN)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Aceragen Inc 's

Name: Aceragen Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACGN Sales vs. its Competitors Q1 2023

Comparing the current results to its competitors, Aceragen Inc reported Revenue increase in the 1 quarter 2023 by 0 % year on year.
The revenue growth was below Aceragen Inc 's competitors' average revenue growth of 0.1 %, achieved in the same quarter.

• List of ACGN Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Aceragen Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 64.09 %

<< ACGN Stock Performance Comparisons

<< See the full list of ACGN competitors

*Market share is calculated based on total revenue.

ACGN's Stock Performance relative to its Competitors

Publicly Traded Peers of Aceragen Inc

Zura Bio Limited
Share Performance

-8.97%

Over The Past 5 Days

Zura Bio Limited

Profile

Zura Bio Limited operates on a business model focused on developing and commercializing innovative bio-based solutions.

More about Zura Bio Limited's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 527.505 mill.	$ - mill.	$ -111.577 mill.

Cullinan Therapeutics Inc
Share Performance

-32.72%

30 Days

Cullinan Therapeutics Inc

Profile

Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.

More about Cullinan Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -204.688 mill.

Biogen Inc
Share Performance

+27.30%

This Year

Biogen Inc

Profile

Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.

More about Biogen Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 33,591.824 mill.	$ 9,937.400 mill.	$ 1,371.900 mill.

Amgen Inc
Share Performance

+49.73%

One Year

Amgen Inc

Profile

Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.

More about Amgen Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 220,885.760 mill.	$ 38,095.000 mill.	$ 8,743.000 mill.

Alvotech
Share Performance

+17.60%

This Year

Alvotech

Profile

Alvotech develops and commercializes biosimilar pharmaceutical products.

More about Alvotech's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ 588.904 mill.	$ 27.919 mill.

38 more competitors available

Sources: Aceragen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 18, 2026 3:21 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aceragen Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.